buparlisib and Osteolysis

The plasma cell malignancy multiple myeloma (MM) is unique amongst haematological malignancies in its capacity to cause osteoclast-mediated skeletal destruction. The PI3K/Akt pathway mediates proliferation, survival and drug resistance in MM plasma cells and is also involved in regulating the formation and activity of bone-forming osteoblasts and bone-resorbing osteoclasts. NVP-BKM120 (Buparlisib, Novartis) is a PI3K inhibitor that is currently undergoing clinical evaluation in several tumour settings. In this study, we have examined the anti-tumorigenic effects of BKM120 in an immunocompetent mouse model of MM and its effects on osteoblast and osteoclast formation and function. BKM120 treatment (40 mg/kg) resulted in a significant decrease in serum paraprotein and tumour burden, and μCT analysis of the proximal tibia revealed a significant reduction in the number of osteolytic bone lesions in BKM120-treated animals. BKM120 also mediated a significant increase in serum levels of the osteoblast marker P1NP, and a significant decrease in serum levels of the osteoclast marker TRAcP5. In vitro, BKM120 decreased MM plasma cell proliferation, osteoclast formation and function, and promoted osteoblast formation and function. These findings suggest that, in addition to its anti-tumour properties, BKM120 could be used to treat osteolytic bone disease in MM patients.

Topics: Aminopyridines; Animals; Apoptosis; Blotting, Western; Bone Diseases; Cell Cycle; Cell Proliferation; Disease Models, Animal; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Mice; Mice, Inbred C57BL; Morpholines; Multiple Myeloma; Osteoclasts; Osteolysis; Phosphoinositide-3 Kinase Inhibitors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays